Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Yoshihara

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
Regenerative Therapy|May 13, 2024
Hepatic arterial infusion of autologous CD34<sup>+</sup> cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trialToru Nakamura, Atsutaka Masuda, Makoto Kako, et al.
International Journal of Hematology|September 5, 2023
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma ForumYuji Shimura, Hirohiko Shibayama, Aya Nakaya, et al.
International Journal of Hematology|September 22, 2020
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registryAya Nakaya, Takae Kohara, Hirohiko Shibayama, et al.
Scientific Reports|March 29, 2023
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulinYutaka Shimazu, Junya Kanda, Satoru Kosugi, et al.
Leukemia|April 21, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AMLYoshikazu Ikoma, Nobuhiko Nakamura, Yuto Kaneda, et al.
Therapeutic Advances in Hematology|December 19, 2022
Monocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomideYutaka Shimazu, Junya Kanda, Hitomi Kaneko, et al.
Leukemia Research Reports|December 11, 2023
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma ForumAya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, et al.
Blood Advances|July 1, 2025
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGICYu Akahoshi, Yoshihiro Inamoto, Nikolaos Spyrou, et al.
Nature Communications|May 15, 2021
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemiaYotaro Ochi, Kenichi Yoshida, Ying-Jung Huang, et al.
Blood|March 6, 2026
BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALLKaito Mimura, Akira Kaino, Yotaro Ochi, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Regenerative Therapy|May 13, 2024
Hepatic arterial infusion of autologous CD34<sup>+</sup> cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trialToru Nakamura, Atsutaka Masuda, Makoto Kako, et al.
International Journal of Hematology|September 5, 2023
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma ForumYuji Shimura, Hirohiko Shibayama, Aya Nakaya, et al.
International Journal of Hematology|September 22, 2020
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registryAya Nakaya, Takae Kohara, Hirohiko Shibayama, et al.
Scientific Reports|March 29, 2023
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulinYutaka Shimazu, Junya Kanda, Satoru Kosugi, et al.
Leukemia|April 21, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AMLYoshikazu Ikoma, Nobuhiko Nakamura, Yuto Kaneda, et al.
Therapeutic Advances in Hematology|December 19, 2022
Monocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomideYutaka Shimazu, Junya Kanda, Hitomi Kaneko, et al.
Leukemia Research Reports|December 11, 2023
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma ForumAya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, et al.
Blood Advances|July 1, 2025
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGICYu Akahoshi, Yoshihiro Inamoto, Nikolaos Spyrou, et al.
Nature Communications|May 15, 2021
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemiaYotaro Ochi, Kenichi Yoshida, Ying-Jung Huang, et al.
Blood|March 6, 2026
BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALLKaito Mimura, Akira Kaino, Yotaro Ochi, et al.
Pageof 15